Investment Institute
Weekly Market Update

Take Two: China relaxes pandemic lockdown restrictions; G7 sets Russia oil price cap

  • 12 December 2022 (5 min read)

What do you need to know?

China relaxed some of its strictest COVID-19 rules, paving the way for a re-opening of the world’s second-largest economy. Citizens can now travel more freely inside China and quarantine at home rather than in state-run facilities, while whole neighbourhoods or cities will no longer be locked down. The move was viewed partly as a response to protests against the strict controls, despite a record number of daily new cases recently. While the easing of restrictions may boost economic growth, experts warned a jump in new cases could overwhelm the country’s healthcare system. November’s trade report showed deceleration in both export and import growth, indicating modest economic momentum that may be troubling authorities in Beijing.

Around the world

The Eurozone economy expanded by more than expected – at 0.3% in the third quarter (Q3) from a previous estimate of 0.2% – on the back of fixed capital investment and household consumption. Despite suggesting the Eurozone was likely “close to peak inflation”, European Central Bank (ECB) Chief Economist Philip Lane hinted that interest rate hikes would have to continue, albeit at a slower pace. Meanwhile, the Japanese economy shrank less than initially estimated in Q3, by an annualised 0.8%. While still a sharp drop from the 4.5% growth recorded in Q2, the upward revision may offer an early sign of recovery.

Figure in focus: $60

G7 countries set a $60-per-barrel price cap on Russian seaborne crude oil – seen as an attempt to curtail Russian oil revenues. The price limit, which entered into force on 5 December, was lower than the $65-$70 initially proposed, but well above the discounted prices at which countries have purchased Russian crude in recent months. Meanwhile, concerns over recession and weakening fuel demand pushed oil prices to their lowest levels of the year, with Brent Crude futures well below $77 a barrel on Friday morning.

Words of wisdom:

Biocredits: A short name for biodiversity credits and a potential tool in the basket of solutions for addressing degradation of the natural environment. Still in their infancy, biocredits are designed to incentivise the flow of capital towards conservation and restoration projects. Research released to coincide with the COP15 biodiversity conference in Canada found they may be a better option than offsets, which could end up harming the environment. However, they will likely face issues around verification and traceability, as has been the case with similar schemes related to carbon emissions.

What’s coming up

Monetary policy dominates the week ahead. On Wednesday the US Federal Reserve meets to decide on interest rates, and announce its latest economic projections, while the Bank of England and ECB hold their own meetings on Thursday. In terms of economic updates, final estimates for US and UK inflation rates during November are reported on Tuesday and Wednesday respectively. Flash Purchasing Managers’ Indices for the Eurozone, Japan, the UK and US are announced on Friday.

Related Articles

Weekly Market Update

Take Two: China growth slows and population falls; global bond issuance soars

  • by AXA Investment Managers
  • 23 January 2023 (3 min read)
Weekly Market Update

Take Two: Fed and ECB signal more rate hikes to come, new energy breakthrough announced

  • by AXA Investment Managers
  • 19 December 2022 (3 min read)
Weekly Market Update

Take Two: G20 countries to calibrate pace of rate hikes; Japan GDP unexpectedly contracts

  • by AXA IM Investment Institute
  • 21 November 2022 (5 min read)

    Disclaimer

    This website is published by AXA Investment Managers Asia (Singapore) Ltd. (Registration No. 199001714W) for general circulation and informational purposes only. It does not constitute investment research or financial analysis relating to transactions in financial instruments, nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. It has been prepared without taking into account the specific personal circumstances, investment objectives, financial situation or particular needs of any particular person and may be subject to change without notice. Please consult your financial or other professional advisers before making any investment decision.

    Due to its simplification, this publication is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this publication is provided based on our state of knowledge at the time of creation of this publication. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    All investment involves risk, including the loss of capital. The value of investments and the income from them can fluctuate and investors may not get back the amount originally invested.

    Some of the Services and/or products may not be available for offer to retail investors.

    This publication has not been reviewed by the Monetary Authority of Singapore.